Zobrazeno 1 - 10 of 54 pro vyhledávání: '"Lis Smedegaard Andersen"'
3
Response to 'To switch or not to switch':the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al
Autor: Bente Glintborg, Anne Gitte Loft, Salome Kristensen, Inge Juul Sørensen, Frank Mehnert, Natalia Manilo, Johnny Lillelund Raun, Dorte Dalsgaard Pedersen, Jakob Espesen, Stavros Chrysidis, Hanne Merete Lindegaard, Lis Smedegaard Andersen, Oliver Hendricks, Merete Lund Hetland, Asta Linauskas, Niels Steen Krogh, Henrik Nordin, Inger Marie Jensen Hansen, D V Jensen, Susanne Højmark Jakobsen, Jolanta Grydehøj, Emina Omerovic, Kamilla Danebod, Emil Barner Dalgaard
Publikováno v: Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to ''To switch or not to switch' : the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4, e37 . https://doi.org/10.1136/annrheumdis-2018-214952
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to To switch or not to switch' : The missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4, e37 . https://doi.org/10.1136/annrheumdis-2018-214952
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to ''To switch or not to switch' : the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4 . https://doi.org/10.1136/annrheumdis-2018-214952
Thank you for the interest1 in our recent publication, in which we explored treatment outcomes following a Danish mandatory switch from originator to biosimilar etanercept (SB4, 50 mg) in routine care.2 We showed that of the 2061 patients who were re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b933c58f95be759c886ede1d15b976a
https://vbn.aau.dk/da/publications/9eba4499-3a28-4c04-b60d-d6ab174db85c
Zobrazit plný text záznamu
4
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Autor: Stavros Chrysidis, B. Glintborg, Niels Steen Krogh, Lis Smedegaard Andersen, Jimmi Sloth Olsen, Dorte Vendelbo Jensen, Jolanta Grydehøj, Michael Veedfald Sørensen, Salome Kristensen, Natalia Manilo, Merete Lund Hetland, Mette Klarlund, Oliver Hendricks, Inge Juul Sørensen, Sabine Sparre Dieperink, Asta Linauskas, Inger Marie Jensen Hansen, Henrik Nordin, Jakob Espesen, Kathrine Lederballe Grøn, Dorte Dalsgaard Pedersen, Lars Pedersen, Hanne Merete Lindegaard, Anne Gitte Loft
Publikováno v: Glintborg, B, Sørensen, I J, Loft, A G, Lindegaard, H, Linauskas, A, Hendricks, O, Hansen, I M J, Jensen, D V, Manilo, N, Espesen, J, Klarlund, M, Grydehøj, J, Dieperink, S S, Kristensen, S, Olsen, J S, Nordin, H, Chrysidis, S, Dalsgaard Pedersen, D, Sørensen, M V, Andersen, L S, Grøn, K L, Krogh, N S, Pedersen, L & Hetland, M L 2017, ' A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis : 1-year clinical outcomes from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1426-1431 . https://doi.org/10.1136/annrheumdis-2016-210742
Glintborg, B, Sørensen, I J, Loft, A G, Lindegaard, H, Linauskas, A, Hendricks, O, Hansen, I M J, Jensen, D V, Manilo, N, Espesen, J, Klarlund, M, Grydehøj, J, Dieperink, S S, Kristensen, S, Olsen, J S, Nordin, H, Chrysidis, S, Dalsgaard Pedersen, D, Sørensen, M V, Andersen, L S, Grøn, K L, Krogh, N S, Pedersen, L, Hetland, M L & all departments of rheumatology in Denmark 2017, ' A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis : 1-year clinical outcomes from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1426-1431 . https://doi.org/10.1136/annrheumdis-2016-210742
ObjectivesAccording to guidelines, a nationwide non-medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8575d080f35c2e1d089ff61ce2e62eb4
https://doi.org/10.1136/annrheumdis-2016-210742
Zobrazit plný text záznamu
5
To switch or not to switch:results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
Autor: Johnny Lillelund Raun, Jolanta Grydehøj, D V Jensen, Inger Marie Jensen Hansen, Hanne Merete Lindegaard, Anne Gitte Loft, Emina Omerovic, Kamilla Danebod, Oliver Hendricks, Asta Linauskas, Henrik Nordin, Merete Lund Hetland, Stavros Chrysidis, Inge Juul Sørensen, Dorte Dalsgaard Pedersen, Susanne Højmark Jakobsen, Salome Kristensen, Frank Mehnert, Lis Smedegaard Andersen, Niels Steen Krogh, Emil Barner Dalgaard, B. Glintborg, Natalia Manilo, Jakob Espesen
Publikováno v: Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2019, ' To switch or not to switch : results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 78, no. 2, pp. 192-200 . https://doi.org/10.1136/annrheumdis-2018-213474
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2019, ' To switch or not to switch: Results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 78, pp. 192-200 . https://doi.org/10.1136/annrheumdis-2018-213474
ObjectivesReal-world evidence on effectiveness of switching to biosimila r etanercept is scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) to biosimilar (SB4) etanercept was issued for patients with rheumatoid
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c302890950b7f04e11e32e0f3a5fd9ec
https://vbn.aau.dk/da/publications/e6e32571-23f8-49ba-9a63-52682abf94c9
Zobrazit plný text záznamu
7
Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis:Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry
Autor: B. Glintborg, Abdiweli Awil Mohamoud, Mikkel Østergaard, D. G. A. Kraus, Laura Danielsen, Johnny Lillelund Raun, Niels Steen Krogh, Marcin Ryszard Kowalski, Inger Marie Jensen Hansen, Jens Kristian Pedersen, Lene Dreyer, Oliver Hendricks, Henrik Nordin, Anne Gitte Loft, R. Pelck, Jakob Esbesen, Nabil Al Chaer, Inge Juul Sørensen, Merete Lund Hetland, Annette Schlemmer, S. R. Christensen, Lone Salomonsen, Lis Smedegaard Andersen
Publikováno v: Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D, Christensen, S R, Hansen, I M, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D G A, Christensen, S R, Hansen, I M J, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D G A, Christensen, S R, Jensen Hansen, I M, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Objective.To compare baseline disease activity and treatment effectiveness in biologic-naive patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) who initiate tumor necrosis factor inhibitor (TNFi) treatmen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cd77a674a776528ab55f6cdfa54f0c0
https://pure.au.dk/portal/da/publications/ankylosing-spondylitis-versus-nonradiographic-axial-spondyloarthritis(a4ec44b6-168b-422f-9d65-af16decdb758).html
Zobrazit plný text záznamu
8
Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci
Autor: Anne Gitte Loft, Oliver Hendricks, Asta Linauskas, Henrik Nordin, Natalia Manilo, Emina Omerovic, Kamilla Danebod, Jakob Espesen, Dorte Dalsgaard Pedersen, Niels Steen Krogh, Lis Smedegaard Andersen, Inge Juul Sørensen, Hanne Merete Lindegaard, Susanne Højmark Jakobsen, Bente Glintborg, Emil Barner Dalgaard, Inger Marie Jensen Hansen, D V Jensen, Stavros Chrysidis, Jolanta Grydehøj, Salome Kristensen, Frank Mehnert, Johnny Lillelund Raun, Merete Lund Hetland
Publikováno v: Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci ', Annals of the Rheumatic Diseases, vol. 79, no. 2, e14 . https://doi.org/10.1136/annrheumdis-2018-214788
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Response to : 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB 4 : Possible fallout on non-medical switching' by Cantini and Benucci ', Annals of the Rheumatic Diseases, vol. 79, no. 2, e14 . https://doi.org/10.1136/annrheumdis-2018-214788
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci ', Annals of the Rheumatic Diseases, vol. 79, no. 2, pp. e14 . https://doi.org/10.1136/annrheumdis-2018-214788
Thank you for the interest in our publication based on data from the Danish DANBIO registry regarding 2061 patients who were eligible for a mandatory non-medical switch from originator to biosimilar etanercept in routine care.1 2 The marketing of bio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1731af57f569d923b872eebff8daaa7
https://doi.org/10.1136/annrheumdis-2018-214788
Zobrazit plný text záznamu
9
Comparison of tumor necrosis factor alpha inhibitor inhibitor effectiveness in ankylosing spondylitis and nonradiographical axial spondylitis, and the impact of HLA-B27 status. Observational cohort study from the nationwide DANBIO registry
Autor: Bente Glintborg, Inge Juul Sørensen, Mikkel Østergaard, Lene Dreyer, Mahamoud Abdiweli awil, Niels Steen Krogh, Oliver Hendricks, Lis Smedegaard-Andersen, Johnny Lillelund Raun, Marcin Ryszard Kowalski, Laura Danielsen, Randi Pelck, Henrik Nordin, Jens Kristian Pedersen, Dorte Gunver Andersen Kraus, Susan Ringskær Christensen, Inger Marie Jensen Hansen, Jakob Esbensen, Annette Schlemmer, Anne Gitte Loft, Nabil Al Chaer, Lone Salomonsen, Merete Lund Hetland
Publikováno v: Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Abdiweli awil, M, Steen Krogh, N, Hendricks, O, Smedegaard-Andersen, L, Lillelund Raun, J, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D G A, Ringskær Christensen, S, Jensen Hansen, I M, Esbensen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2016, ' Comparison of tumor necrosis factor alpha inhibitor inhibitor effectiveness in ankylosing spondylitis and nonradiographical axial spondylitis, and the impact of HLA-B27 status. Observational cohort study from the nationwide DANBIO registry ', EULAR 2016, London, United Kingdom, 08/06/2016-11/06/2016 .
University of Southern Denmark
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f97009612502da37e61acae72af5f8b5
https://portal.findresearcher.sdu.dk/da/publications/73ca4083-af8f-4075-a61a-1ea2aaa0ffc9
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje